Research
Hormonal
Inhibition of intestinal bile salt hydrolase (BSH) activity by compounds like theabrownin or riboflavin increases conjugated bile acids in the distal ileum, which inhibits intestinal FXR signaling and upregulates hepatic CYP7B1, thereby promoting the alternative bile acid pathway.
Consider incorporating Pu-erh tea or other sources of theabrownin into your diet. These compounds may inhibit bacterial enzymes in the gut, leading to a favorable shift in bile acid signaling that supports metabolic health.
ModerateSupportsMEDIUM confidence
oral administration of TB in mice suppressed the activity of intestinal bacterial BSH enzymes... accumulation of conjugated BAs in the distal ileum... inhibited intestinal FXR and downstream FGF15-FGFR4 signaling and thus, upregulated the BA synthesis genes... CYP7B1
Why this rating
Supported by multiple studies cited in the review, including mouse models and mechanistic verification with FXR agonists/antagonists.
Source
Targeting the alternative bile acid synthetic pathway for metabolic diseases
Wei Jia et al. · Protein & Cell · 2020
DOI 10.1007/s13238-020-00804-9
narrative_reviewCited 318×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Activation of the alternative bile acid synthetic pathway, specifically via increased CYP7B1 expression and non-12α-hydroxylated bile acids (e.g., CDCA, TUDCA), improves glucose and lipid metabolism by reducing lipid absorption and enhancing energy expenditure.Moderate
- High levels of 12α-hydroxylated bile acids (derived from the classical pathway) are associated with metabolic disorders like insulin resistance and type 2 diabetes, whereas a higher ratio of non-12α-hydroxylated bile acids is beneficial.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →